SNY Jan 2025 50.000 call
- Yahoo Finance Video
Novavax shares skyrocket on $1.2 billion Sanofi vaccine deal
Novavax (NVAX) shares are skyrocketing after announcing a $1.2 billion deal with Sanofi (SNY) to commercialize a combined COVID-19 and flu shot. Yahoo Finance's Anjalee Khemlani joins The Morning Brief to report more on the story. The Novavax-Sanofi deal also includes co-commercialization of the COVID-19 vaccine currently on the market. Novavax will be entitled to an additional $200 million for any new vaccines involving its adjuvant. Sanofi will receive a minority stake of less than 5% in Novavax and will invest $70 million. Shares of Novavax jumped more than 120% following the news. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Melanie Riehl
- Yahoo Finance Video
Stock markets, China tariffs, Novavax and Sanofi: 3 Things
The major stock market indexes (^DJI, ^IXIC, ^GSPC) are on the road to closing out the first full trading week of May on a high note, alongside several of its European counterparts: the FTSE 100 (^FTSE), the DAX Performance Index (^GDAXI), and the CAC 40 (^FCHI). President Biden is reportedly set to announce updates on Trump-era trade tariffs on China. Novavax (NVAX) shares are skyrocketing over 110% on news of the biotech company's plans to licensing deal with Sanofi (SNY, SAN.PA) to co-commercialize its COVID-19 vaccine For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Luke Carberry Mogan.
- Barrons.com
Novavax Stock Surges 120% on $1.4 Billion Deal With Sanofi
Novavax the pharmaceutical company that last year warned that falling sales of its Covid-19 vaccine could put it out of business, said it reached a $1.4 billion deal with French company Sanofi to commercialize its existing treatment and develop a new one. Shares spiked 120% in premarket trading to $10.02. Sanofi agreed to pay $500 million upfront and spend another $700 million when the company hits development, regulatory and launch milestones, Novavax said in a statement Friday.
